再生元製藥公司 REGN 深 滬
交易中 09-17 11:09:45 美东时间
585.68
+10.620
+1.85%
華盛通- 最 高586.29
- 今 開576.31
- 成交量 17.67万股
- 最 低 576.31
- 昨 收 575.06
- 總市值 632.53亿
- 52周最高 1058.96
- 市盈率 靜 15.28
- 換手率 0.16%
- 52周最低 475.6069
- 委 比 -89.47%
- 總股本 1.08亿
- 歷史最高 1208.5599
- 量 比 1.01
- 振 幅 1.74%
- 歷史最低 40.19
- 每 手 1
- 風險率 106.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Regeneron Says Phase 3 OPTIMA Trial Of Garetosmab For Fibrodysplasia Ossificans Progressiva Met Its Primary Endpoint
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitationGaretosmab is the first and only treatment to demonstrate a dramatic reduction in both number
今天 19:09
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
The 26-week COURAGE trial demonstrates that combining semaglutide with trevogrumab reduces semaglutide-induced lean mass loss by about half while enhancing fat loss. The treatment also showed improvements in metabolic and lipid parameters across all groups. However, adverse events and tolerability issues, particularly with the triplet combination, highlighted the need for further study to confirm safety and efficacy.
今天 13:30
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
Regeneron Pharmaceuticals announced that the Phase 3 OPTIMA trial for garetosmab met its primary endpoint in treating fibrodysplasia ossificans progressiva (FOP). At 56 weeks, both doses (3 mg/kg and 10 mg/kg) of garetosmab showed a significant reduction in new bone lesions, with a 94% and 90% reduction respectively compared to placebo. The treatment also led to over 99% reduction in the total volume of new lesions. The Independent Data Monitorin...
今天 11:00
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
今天 00:29
创新药的“收获季”：从亏损到盈利，药企中报答卷亮了
“当行业还在去库存，他们已经扭亏为盈；当市场还在对抗内卷时，他们已经把产品卖到全球。” 2025年半年报收官，医药生物上市公司整体交出一份相对平淡的...
09-12 17:15
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Regeneron's Phase 3 EMPOWER-Lung 3 trial shows Libtayo plus chemotherapy doubles five-year overall survival (19.4%) in advanced NSCLC patients, compared to 8.8% with chemotherapy alone. The combination demonstrated superior efficacy with a median OS of 21.1 months (vs 12.9 months), PFS of 8.2 months (vs 5.5 months), and ORR of 43.6% (vs 22.1%). Subgroup analyses across histologies and PD-L1 expression levels confirmed consistent benefits, with no...
09-09 11:00
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development.
09-09 01:11
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Regeneron reports successful Phase 3 trials for allergen-blocking antibodies targeting cat (FelD1) and birch (BetV1) allergies, showing significant reduction in symptoms like eye itching, redness, and skin reactivity. These findings support advanced development of the innovative treatments aimed at rapid and durable allergy relief.
09-08 10:30
Regeneron Advances Melanoma Treatment with Long-term Study Update
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinic...
09-08 00:59
